Context: Thyroid hormone acts as a fundamental regulator in cardiovascular homeostasis in pathophysiological conditions.
involves the interventricular septum and left ventricle (7) . Patients with HCM suffer a greater risk of ventricular arrhythmias and heart failure than does the general population, and accumulating evidence suggests that HCM is the leading cause of sudden cardiac death in the young (8) . However, there are limited data regarding thyroid hormone levels and the prognosis of patients with HCM.
Animal experiments have demonstrated that thyroid hormones have complex effects on myocytes, matrix, and ventricular function (1, 9) . In hyperthyroidism, cardiac hypertrophy is induced by the overproduction of thyroid hormones, whereas our previous work interestingly revealed that hypothyroid status could also lead to ventricular remodeling and impaired cardiac function (10) . Clinical literature in this specialized field is rare and only provides the relationship between thyroid hormones and cardiac function parameters. Cohorts with long-term follow-up are needed to establish the role of thyroid status in HCM and provide the opportunity for early interventions to address clinical risk factors and improve patient prognosis.
Identifying high-risk HCM patients plays a key role in treatment strategy selection, and increased attention has been focused on various circulating biologically active substances, also known as plasma biomarkers (11, 12) . Neurohormonal activation of N-terminal pro-brain natriuretic peptides (NT-proBNPs) remains one of the established prognostic determinants of disease progression in HCM patients, as it is a marker of myocardial cell necrosis and a strong predictor of mortality (13) . With complex direct and indirect effects on myocardium, thyroid hormone levels appear as a more promising monitoring index in guiding the risk classification and treatment of HCM.
Based on the aforementioned information, we hypothesized that thyroid hormone could serve as a risk predictor in hypertrophic obstructive cardiomyopathy (HOCM) and accurately improve risk stratification combined with traditional biomarkers. We tested the hypothesis with complete information of thyroid function profile from a well-characterized population of 756 consecutive patients with HOCM.
Methods

Ethics statement
The study was in accordance with the ethical guidelines of the Declaration of Helsinki and China's regulations and guidelines on good clinical practice and was approved by the Ethics Committee of Fuwai Hospital. Before the start of the study, we received written informed consent from all participants.
Study participants
All patients in this study were evaluated at Fuwai Hospital (National Center of Cardiovascular Diseases, Beijing, China).
Between 1 October 2009 and 31 December 2014, a total of 965 patients (age $ 16 years) were diagnosed with HOCM. Among those participants, 756 subjects with complete information on thyroid function, clinical information, and medical history, in the absence of hyperthyroidism (FT3 . 4.09 pg/mL) and any other heart or systemic diseases that induced cardiac hypertrophic changes (such as uncontrolled hypertension of home blood pressure monitoring $ 140/90 mm Hg, congenital heart disease, cardiac valve disease, and amyloidosis), were selected. Patients who were taking drugs that may affect thyroid function, including thyroxine, liothyronine, amiodarone, corticosteroids, or antithyroid drugs, were excluded. Patients with a history of thyroid disorder, hypothalamicpituitary disorder, and autoimmune disease were also excluded. Patients were divided into three groups according to the FT3 levels: tertile 1 (FT3 , 2.81 pg/mL, n = 247), tertile 2 (2.81 pg/mL # FT3 # 3.11 pg/mL, n = 250), tertile 3 (4.09 $ FT3 . 3.12 pg/mL, n = 259). The diagnosis of HOCM was based on Elliott et al. (14) : (1) wall thickness $ 15 mm in one or more left ventricular myocardial segments, as measured by any imaging technique (echocardiography, cardiac magnetic resonance imaging, or computed tomography); (2) wall thickness 13 to 14 mm with family history, noncardiac symptoms and signs, electrocardiogram abnormalities, laboratory tests, and mutimodality cardiac imaging; (3) patients with left ventricular outflow tract (LVOT) obstruction (LVOTO) were based on dynamic LVOTO due to systolic anterior motion of the mitral valve, with an LVOT gradient $ 30 mm Hg at rest or during physiological provocation such as Valsalva maneuver, standing, and exercise. Significant dynamic LVOTO was documented with two-dimensional and Doppler echocardiography, or in cases in which echocardiography was insufficient, via invasive hemodynamic catheterization with provocation.
Invasive treatment to reduce LVOTO should be considered in patients with an LVOTO gradient $ 50 mm Hg at rest or with provocation, moderate-to-severe symptoms [New York Heart Association (NYHA) class III to IV), and/or recurrent exertional syncope despite maximally tolerated drug therapy. The choice of alcohol septal ablation or surgical myectomy was made through a shared decision-making process after discussing the risks and benefits of each alternative.
Thyroid function test
Thyroid status was evaluated when heart failure symptoms could be controlled under regular oral medication prior to discharge, rather than during the acute phase. The median duration between hospital admission and thyroid function test was 10 days. Twelve-hour fasting blood samples were drawn and the serum levels of thyroid hormone and thyrotropin (TSH) were measured using radioimmunoassay (Immulite 2000; Siemens, Germany) in the Nuclear Medicine Department of Fuwai Hospital. The reference intervals of thyroid and TSH in our laboratory are as follows: TSH, 0.55 to 4.78 mIU/L; FT3, 1.79 to 4.09 pg/mL; free thyroxine (FT4), 0.8 to 1.88 ng/dL; total triiodothyronine (TT3), 0.65 to 1.91 ng/mL; total thyroxine (TT4), 4.29 to 12.47 mg/dL. The primary endpoints of this study were all-cause mortality and cardiac transplantation during long-term follow-up. Mortality and adverse events were retrieved from hospital patient records at the center where follow-up occurred, from civil service population registers, and from information provided by patients themselves and/or their general practitioners. Patients lost to follow-up were censored upon last contact with them. When no events occurred during follow-up, the administrative censoring date was set at 31 December 2016.
Follow-up and endpoints
Statistical analyses
Statistical analysis was assessed with the SPSS 21.0 statistical package for Windows. All continuous variables are presented as means 6 standard deviation, and analysis of variance was used to compare means across multiple groups. The relationships between parametric variables were assessed by multiple linear regression analysis. Initial differences in baseline characteristics between achieved treatment groups were sought in bivariable analysis by using x 2 tests, Fisher's exact tests, Student t tests, and Kruskal-Wallis analysis of variance. Univariate and multivariate Cox proportional hazards model were developed to estimate hazard ratio (HR) with 95% confidence intervals (CIs). These covariables in multivariate analysis were mainly selected for the following reasons: the variable that has significance in univariable analysis is incorporated in the multivariable analysis; the variable is known to be related to both thyroid function and cardiovascular events and thus may act as a potential confounder. Kaplan-Meier analysis was used to study cumulative survival of different groups. A P value , 0.05 was considered significant.
Results
Study population and baseline clinical characteristics
From 1 October 2009 to 31 December 2014, a total of 965 consecutive patients with HOCM (age $ 16 years) were admitted to Fuwai Hospital (National Center of Cardiovascular Diseases, Beijing, China). Among the entire cohort, 756 subjects with complete information of thyroid function, clinical information, and medical history were enrolled into this study. Table 1 shows the baseline clinical characteristics and thyroid hormone levels of the study population. The population was divided into three groups according to the FT3. Patients in tertile 1 had the lowest percentage of males and the lowest percentage of smokers. Significant differences were also detected for LVOT gradient, NYHA functional class, atrial fibrillation (AF), NT-proBNP level, serum creatinine, TSH, FT3, FT4, TT4, and TT3 in the three groups. No significant differences were found regarding comorbidities, medications, implantable cardioverter defibrillator or pacemaker implantation, and invasive treatments. Owing to the poor medical conditions of the China mainland in the past 30 years, patients seldomly recalled clearly their past family medical history in the prior generation. Therefore, the family history of HCM in all three groups was lower than in previous reports (15) . Fig. 1 depicts the comparison of NT-proBNP, FT3, and TT3 with NYHA class I to II and III to IV. The following significant trends were observed: patients with higher NYHA classes yielded elevated levels of NTproBNP (P , 0.001) and reduced levels of FT3 (P = 0.016) and TT3 (P , 0.003).
Correlation analysis of thyroid hormone levels with echocardiographic parameters
Echocardiography was the most frequently used method to evaluate the function and morphology of myocardium in HCM patients, and it was carried out routinely in the present clinical study. The correlation analysis of thyroid hormone levels and echocardiographic parameters is shown in Table 2 . After adjusting for conventional risk factors (age, sex, blood pressure, heart rate) in multiple linear regressions, FT3 showed significantly positive correlation with left ventricular ejection fraction (LVEF; (r = 0.109, P = 0.003). FT4 had a slightly negative correlation with interventricular septal wall thickness (r = 20.083, P = 0.023). Log TSH also showed a slightly positive correlation with LVEF (r = 0.086, P = 0.018), and had a negative correlation with the left ventricular end-diastolic diameter (r = 20.174, P , 0.001).
Prognostic value of the FT3 level in HOCM
After a median follow-up of 44 6 18 months, 43 patients (5.7%) died with rates of 12.6%, 3.6%, and 1.2% in tertiles 1, 2, and 3, respectively. Moreover, orthotropic cardiac transplantation was performed in two patients in tertile 1 due to end-stage heart failure. Among the three groups, patients in tertile 1 of FT3 (FT3 level , 2.81 pg/mL) suffered from the highest risk of reaching all-cause mortality and cardiac transplantation endpoint ( Fig. 2 ; P , 0.001 by log-rank test). Tertile 2 of FT3 also showed a higher trend of reaching composite endpoint, but was not statistically significant (P = 0.069 by log-rank test).
The results of univariate Cox survival analysis for allcause mortality and cardiac transplantation endpoint are shown in Table 3 . In thyroid function profiles, FT3 showed a significant predictive value (HR, 0.111; 95% CI, 0.065 to 0.189; P , 0.001). Age, NT-proBNP, LVEF, LVOT, atrial fibrillation, and serum creatinine were also found to be associated with the composite endpoint.
Two multivariate models were constructed based on inclusion of FT3 as either a continuous variable or categorical variable (tertiles 1, 2, and 3). In multivariate Cox survival analysis model 1, FT3 level (continuous variable) was significantly associated with all-cause mortality and cardiac transplantation (HR, 0.216; 95% CI, 0.083, 0.559; P = 0.002; Table 4 ). In multivariate Cox survival analysis model 2, FT3 , 2.81 pg/mL status was significantly associated with all-cause mortality and cardiac transplantation (HR, 4.918; 95% CI, 1.076, 22.485; P = 0.040; Table 4 ). Atrial fibrillation, LVEF, and NTproBNP were also found to be independently correlated with all-cause mortality and cardiac transplantation in model 2. Furthermore, a receiver operating characteristic curve was performed to determine the cutoff value of FT3 Values are mean 6 standard deviation or n (%).
Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; Cr, serum creatinine; LV, left ventricle. For P values: A, significant difference between three groups; a, Significant difference between the tertile 1 group and tertile 2 group; b, significant difference between the tertile 1 group and tertile 3 group; c, significant difference between the tertile 2 group and tertile 3 group; NS, not significant. a Including eight patients who had resaved alcohol septal ablation before septal myectomy (four in tertile 1 group; two in tertile 2 group; two in tertile for all-cause mortality and cardiac transplantation. The sensitivity and specificity were 79% and 73%, respectively, for FT3 cutoff value of 2.73 pg/mL, with an area under the curve of 0.79 (Supplemental Fig. 1 ).
Discussion
The present study explored the prognostic value of thyroid hormone levels in HOCM and identified FT3 as a significant independent predictor of cardiac events. Among the three groups, FT3 , 2.81 pg/mL status was associated with a higher rate of all-cause mortality and cardiac transplantation endpoint. Significant differences were also detected for LVOT gradient, NYHA functional class, atrial fibrillation, NT-proBNP level, serum creatinine, TSH, FT3, FT4, TT4, and TT3 in all three groups. No significant difference was found regarding comorbidities, medications, implantable cardioverter defibrillator, or pacemaker implantation and invasive treatments. In multivariate Cox survival analysis, low FT3 level was significantly associated with all-cause mortality and cardiac transplantation endpoint. In the present cohort, low FT3 level was an independent predictor for cardiac events and provided more information for assessing the prognosis of HOCM. These findings build on growing evidence suggesting a strong link between low thyroid function and worsening cardiovascular outcomes and, to our knowledge, for the first time show that low T3 could serve as an independent risk predictor for poor prognosis in HOCM patients. Thyroid dysfunction has proven to be an important risk factor in the progression of cardiac diseases, even subtle changes of thyroid hormone levels could adversely affect the prognosis of patients with cardiovascular disorders (5, 16, 17) . Our previous study (4), together with other clinical evidence, suggests that thyroid hormone levels correlate with cardiac function. However, there are limited studies on thyroid function and HCM. Chen et al. (18) reported that high-normal TSH levels may affect the development of heart failure through their association with left ventricular diastolic impairment in HCM patients. Birket et al. (19) reported a simple screen that revealed the collaborative effects of thyroid hormone, insulin-like growth factor-1, and the glucocorticoid analog dexamethasone on the electrophysiology, bioenergetics, and contractile force generation of human pluripotent stem cell-derived cardiomyocytes, which are essential for their effective application in models of HCM. To the best of our knowledge, this was the first clinical study demonstrating that thyroid function can provide more clinically relevant information for assessing the risk of midterm mortality in patients with HCM. However, detailed understanding of mechanisms between the relationship of thyroid dysfunction and HCM are warranted, and these findings may stimulate further study in this interesting topic.
This study indicated that FT3 can adversely influence the cardiovascular system even within normal low range. Accumulating experimental evidence revealed that serum thyroid hormone levels did not accurately reflect cardiac tissue thyroid hormone contents (20) . Multiple animal models of heart failure showed that even though serum FT3 was not decreased, obvious impaired thyroid signaling, including thyroid hormone receptors, membrane transporter of T3, and low cardiac local T3, was observed, which can be preserved from T3 replacement therapy (21-23) . Therefore, serum thyroid hormone concentrations may underestimate the incidence of cardiac local hypothyroidism in heart failure.
Thyroid hormone serves as a master regulator for diverse remodeling processes in the cardiovascular system, ranging from the prenatal period to death. Thyroid hormone promotes beneficial cardiomyocyte shape and improves contractility, relaxation, and survival via reversal of molecular remodeling. Fukuyama et al. (2) reported that T3 inhibits the CREB/CRE signaling pathway and suppresses cytokine expression and vascular smooth muscle cell proliferation, which may account for an antiatherosclerotic effect of thyroid hormone. Thyroid hormone restores metabolic function and improve blood flow both by direct effects on the vessel architecture and by reducing atherosclerosis. Samuel et al. (24) suggested that T3 has an overprotective effect, and therefore they endorsed it as a potential therapeutic approach to treat vascular disease that involves impaired vasodilation.
Accumulating data have shown that low thyroid function contributes to myocardial fibrosis. Myocardial fibrosis has been shown to be associated with worsening prognosis in heart failure patients and represents a principal phenotype of cardiac vulnerability that has a potential to be used as an incremental factor to improve risk stratification (25) . An in vivo experiment revealed that myocardial fibrosis induced by hypothyroidism was attributable to increased expression of pro-a1(I) collage (26) . Animal studies indicated that thyroid hormone replacement therapy can reduce fibrosis as a consequence of favorable regulations in genes related to collagen signaling (23) and reduces the incidence and duration of arrhythmias via remodeling ion channel expression and function.
Biologically active FT3 influences genes that encode several important structural and functional proteins of the myocardium, and it has extensive nongenomic actions on ion pumps and enzymes (27) . In our previous animal experiment, a hypothyroid rat model induced by antithyroid drugs demonstrated that the expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 2a and a-myosin heavy chain were reduced, whereas phospholamban and b-myosin heavy chain were increased with decreased levels of thyroid hormones (10), presenting typical changes of myocardial functional proteins The relationships between parametric variables were assessed by multiple linear regression and were adjusted for conventional risk factors (age, sex, blood pressure, heart rate).
Abbreviations: LV, left ventricle; RV, right ventricle. Figure 2 . Kaplan-Meier curves comparing the probability of outcomes stratified by FT3 for all-cause mortality or cardiac transplantation. in heart failure. Low thyroid function is very frequent in heart failure and is increasingly shown to be a strong and independent predictive marker of poor prognosis in cardiac patients (5, 6, 28, 29) . Therefore, thyroid dysfunction might represent a determining factor in the development and prognosis of cardiovascular conditions, which is highly clinically relevant if standard therapy strategy can be established in these disorders. Despite the encouraging findings, our study has some limitations. Multiple thyroid tests were only available in 78.3% of the initially evaluated patients, so the current study could not resolve the ambiguity due to a transient change of thyroid status, which is frequent in the progress of HCM. The time-related changes of thyroid hormone levels in HCM should be explored in future studies. The second limitation was that thyroid function profiles were evaluated according to serum thyroid hormone levels rather than myocardial tissue level. As mentioned before, myocardial T3 could be downregulated by the induction of type III iodothyronine deiodinase in heart failure (30), which is independent of changes in serum thyroid hormone levels. Further investigation to define the relationship of serum and myocardial tissue thyroid hormone levels in human heart disease is certainly needed. Finally, we performed a single-center study that allowed for a standardized approach and interpretation. Corroboration of our findings in a multicenter setting is required. Nevertheless, the strengths of the present study include the wellcharacterized HOCM cohort, complete information of clinical and thyroid function tests, and the exclusion of drug administration that might affect thyroid profile.
In conclusion, we identified low FT3 level as a significant independent predictor of all-cause mortality and cardiac transplantation for HOCM. The thyroid function status can provide valuable clinically relevant information for assessing the risk of midterm mortality in patients with HOCM. 
